Abstract
AbstractDrug exposure during pregnancy lacks global fetal safety data. The maternal drug exposure birth cohort (DEBC) study, a prospective longitudinal investigation, aims to explore the correlation of maternal drug exposure during pregnancy with pregnancy outcomes, and establish a human biospecimen biobank. Here we describe the process of establishing DEBC and show that the drug exposure rate in the first trimester of pregnant women in DEBC (n = 112,986) is 30.70%. Among the drugs used, dydrogesterone and progesterone have the highest exposure rates, which are 11.97% and 10.82%, respectively. The overall incidence of adverse pregnancy outcomes is 13.49%. Dydrogesterone exposure during the first trimester is correlated with higher incidences of stillbirth, preterm birth, low birth weight, and birth defects, along with a lower incidence of miscarriage/abortion. Due to the limitations of this cohort study, causative conclusions cannot be drawn. Further follow-up and in-depth data analysis are planned for future studies.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. McBride, W. Thalidomide and congenital malformations. Lancet 278, 1358 (1961).
2. Benevent, J., Montastruc, F. & Damase-Michel, C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin. Drug Saf. 16, 1181–1190 (2017).
3. Lacroix, I., Damase-Michel, C., Lapeyre-Mestre, M. & Montastruc, J. L. Prescription of drugs during pregnancy in France. Lancet 356, 1735–1736 (2000).
4. Zhen, J. et al. Specifications for pharmaceutical care in medical institutions. Her. Med. 338, 6–27 (2019).
5. Yang, Y., Chen, C., & Liu, X. Pharmacokinetics and safety of drugs in mother and fetus during pregnancy. Herb. Med. 36, 5 (2017).